USB-002
- Generic Name
- USB-002
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
Phase 2
Terminated
- Conditions
- COVID-19 Virus InfectionSARS Coronavirus 2 InfectionSARS-CoV-2 Infection2019 Novel Coronavirus InfectionRespiratory Distress Syndrome, AdultAdult Respiratory Distress Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- US Biotest, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04778059
- Locations
- 🇺🇸
The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospitals, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath